cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.5whuau
title: Occurrence Download

description: A dataset containing 17 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Salvinia ×molesta D.S.Mitch.",
 "Country is Kenya",
 "HasCoordinate is true"
 ]
}

 The dataset includes 17 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0084061-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.6eth8c
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Salvinia ×molesta D.S.Mitch.",
 "Country is Liberia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0084062-250525065834625/datasets/export for details.
DOI: 10.6084/m9.figshare.29193306
title: Drug-drug interaction between anti-seizure medications in Dravet syndrome and Lennox-Gastaut syndrome

description: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare, severe epileptic encephalopathies requiring complex, individualized treatment due to drug-resistant seizures, non-seizure outcomes, and comorbidities. Polytherapy is an inevitable aspect of managing these conditions, making the management of drug-drug interactions (DDIs) crucial for optimizing efficacy, minimizing toxicity, and addressing broader patient needs. This review discusses current and emerging pharmacological therapies for seizures in DS and LGS. We explore documented and theoretical DDIs between these drugs and other antiseizure medications (ASMs), focusing on pharmacokinetic and pharmacodynamic characteristics. The clinical significance of these DDIs is emphasized, with practical recommendations for their management. Advances in understanding DDIs are key to optimizing treatment, particularly through the combination of ASMs with distinct mechanisms of action. A rational therapeutic approach should consider not only seizure control but also comorbidities. Understanding metabolic pathways involved in pharmacokinetic interactions is essential for predicting and avoiding adverse effects. Digital tools and decision-support apps can assist clinicians in quickly assessing DDIs and selecting the most effective drug combinations. Ongoing research in pharmacogenetics and personalized medicine holds promise for improving the management of complex conditions like DS and LGS, offering potential for better, individualized therapeutic strategies.
DOI: 10.6084/m9.figshare.29193306.v2
title: Drug-drug interaction between anti-seizure medications in Dravet syndrome and Lennox-Gastaut syndrome

description: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare, severe epileptic encephalopathies requiring complex, individualized treatment due to drug-resistant seizures, non-seizure outcomes, and comorbidities. Polytherapy is an inevitable aspect of managing these conditions, making the management of drug-drug interactions (DDIs) crucial for optimizing efficacy, minimizing toxicity, and addressing broader patient needs. This review discusses current and emerging pharmacological therapies for seizures in DS and LGS. We explore documented and theoretical DDIs between these drugs and other antiseizure medications (ASMs), focusing on pharmacokinetic and pharmacodynamic characteristics. The clinical significance of these DDIs is emphasized, with practical recommendations for their management. Advances in understanding DDIs are key to optimizing treatment, particularly through the combination of ASMs with distinct mechanisms of action. A rational therapeutic approach should consider not only seizure control but also comorbidities. Understanding metabolic pathways involved in pharmacokinetic interactions is essential for predicting and avoiding adverse effects. Digital tools and decision-support apps can assist clinicians in quickly assessing DDIs and selecting the most effective drug combinations. Ongoing research in pharmacogenetics and personalized medicine holds promise for improving the management of complex conditions like DS and LGS, offering potential for better, individualized therapeutic strategies.
DOI: 10.6084/m9.figshare.29253944
title: Mechanism-based drug safety testing using innovative <i>in vitro</i> liver models: from DILI prediction to idiosyncratic DILI liability assessment

description: Idiosyncratic drug-induced liver injury (iDILI) remains unpredictable. As adverse responses arise in a small fraction of patients, drugs often fail in later drug development stages or post-approval, thereby tremendously increasing costs and putting patients at risk, highlighting the need for accurate early identification of iDILI liabilities. Using articles from the last 5 years (PubMed), iDILI risk factors are described, <i>in vitro</i> liver models and mechanism-based readout strategies are evaluated on their potential to enable iDILI liability assessment. Various <i>in vitro</i> liver models are established for disease modeling and DILI prediction. Drawbacks for each of these seem inevitable, making the evaluation of their application domain and iDILI liability assessment potential crucial. A tiered approach could be considered, whereby compounds are initially screened and flagged using simple fit-for-purpose models for DILI prediction, followed by multicellular liver models that integrate the current knowledge of iDILI onset in combination with mechanistic readouts. Multiplexing models within an integrated mechanism-based testing strategy could improve the safety assessment accuracy. Defined <i>in vitro</i> models should integrate critical hepatocyte intrinsic risk factors as well as adaptive immune system components to refine iDILI liability assessment.
DOI: 10.6084/m9.figshare.29253944.v2
title: Mechanism-based drug safety testing using innovative <i>in vitro</i> liver models: from DILI prediction to idiosyncratic DILI liability assessment

description: Idiosyncratic drug-induced liver injury (iDILI) remains unpredictable. As adverse responses arise in a small fraction of patients, drugs often fail in later drug development stages or post-approval, thereby tremendously increasing costs and putting patients at risk, highlighting the need for accurate early identification of iDILI liabilities. Using articles from the last 5 years (PubMed), iDILI risk factors are described, <i>in vitro</i> liver models and mechanism-based readout strategies are evaluated on their potential to enable iDILI liability assessment. Various <i>in vitro</i> liver models are established for disease modeling and DILI prediction. Drawbacks for each of these seem inevitable, making the evaluation of their application domain and iDILI liability assessment potential crucial. A tiered approach could be considered, whereby compounds are initially screened and flagged using simple fit-for-purpose models for DILI prediction, followed by multicellular liver models that integrate the current knowledge of iDILI onset in combination with mechanistic readouts. Multiplexing models within an integrated mechanism-based testing strategy could improve the safety assessment accuracy. Defined <i>in vitro</i> models should integrate critical hepatocyte intrinsic risk factors as well as adaptive immune system components to refine iDILI liability assessment.
DOI: 10.6084/m9.figshare.29193306.v1
title: Drug-drug interaction between anti-seizure medications in dravet syndrome and lennox-gastaut syndrome

description: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare, severe epileptic encephalopathies requiring complex, individualized treatment due to drug-resistant seizures, non-seizure outcomes, and comorbidities. Polytherapy is an inevitable aspect of managing these conditions, making the management of drug-drug interactions (DDIs) crucial for optimizing efficacy, minimizing toxicity, and addressing broader patient needs. This review discusses current and emerging pharmacological therapies for seizures in DS and LGS. We explore documented and theoretical DDIs between these drugs and other antiseizure medications (ASMs), focusing on pharmacokinetic and pharmacodynamic characteristics. The clinical significance of these DDIs is emphasized, with practical recommendations for their management. Advances in understanding DDIs are key to optimizing treatment, particularly through the combination of ASMs with distinct mechanisms of action. A rational therapeutic approach should consider not only seizure control but also comorbidities. Understanding metabolic pathways involved in pharmacokinetic interactions is essential for predicting and avoiding adverse effects. Digital tools and decision-support apps can assist clinicians in quickly assessing DDIs and selecting the most effective drug combinations. Ongoing research in pharmacogenetics and personalized medicine holds promise for improving the management of complex conditions like DS and LGS, offering potential for better, individualized therapeutic strategies.
DOI: 10.6084/m9.figshare.29253944.v1
title: Mechanism-based drug safety testing using innovative <i>in vitro</i> liver models: from DILI prediction to idiosyncratic DILI liability assessment

description: Idiosyncratic drug-induced liver injury (iDILI) remains unpredictable. As adverse responses arise in a small fraction of patients, drugs often fail in later drug development stages or post-approval, thereby tremendously increasing costs and putting patients at risk, highlighting the need for accurate early identification of iDILI liabilities. Using articles from the last five years (PubMed), iDILI risk factors are described, <i>in vitro</i> liver models and mechanism-based readout strategies are evaluated on their potential to enable iDILI liability assessment. Various <i>in vitro</i> liver models are established for disease modeling and DILI prediction. Drawbacks for each of these seem inevitable, making the evaluation of their application domain and iDILI liability assessment potential crucial. A tiered approach could be considered, whereby compounds are initially screened and flagged using simple fit-for-purpose models for DILI prediction, followed by multicellular liver models that integrate the current knowledge of iDILI onset in combination with mechanistic readouts. Multiplexing models within an integrated mechanism-based testing strategy could improve the safety assessment accuracy. Defined <i>in vitro</i> models should integrate critical hepatocyte intrinsic risk factors as well as adaptive immune system components to refine iDILI liability assessment.
DOI: 10.5281/zenodo.15194399
title: Global mangrove natural regeneration potential assessment for identifying carbon potentials of natural regeneration and plantation

description: Includes mangrove natural regeneration potential maps, as well as map uncertainty and extrapolation classifications.
DOI: 10.5281/zenodo.15194400
title: Global mangrove natural regeneration potential assessment for identifying carbon potentials of natural regeneration and plantation

description: Includes mangrove natural regeneration potential maps, as well as map uncertainty and extrapolation classifications.
DOI: 10.6084/m9.figshare.28458680
title: Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database

description: T-cell engagers (TCEs) are transformative immunotherapies with significant potential in treating hematologic malignancies and solid tumors. However, their real-world safety profiles remain inadequately characterized. Using the FDA Adverse Event Reporting System (FAERS) database (October 2019 – September 2024, 8,747,158 reports), we analyzed adverse events (AEs) associated with nine TCEs. Disproportionality analysis identified overreported AEs, with 11,963 unique reports analyzed after deduplication. Blinatumomab was the most reported TCE (<i>n</i> = 4,950), and Tarlatamab the least (<i>n</i> = 185). Predominant AEs included immune system disorders, particularly cytokine release syndrome (IC<sub>025</sub> range: 6.08–7.47). Drug-specific signals included reproductive system and breast disorders (IC<sub>025</sub>: 2.74) and vascular disorders (IC<sub>025</sub>: 2.25) with Tebentafusp, renal and urinary disorders with Epcoritamab (IC<sub>025</sub>: 1.84), and eye disorders with Elranatamab (IC<sub>025</sub>: 1.81). Novel AEs were also uncovered, including second malignant neoplasms, vasogenic cerebral edema with Mosunetuzumab (IC<sub>025</sub>: 5.77, ROR<sub>025</sub>: 56.29), and hydronephrosis with Epcoritamab (IC<sub>025</sub>: 7.50, ROR<sub>025</sub>: 180.70). Early-onset events (0.5–9.5 days) were linked to four TCEs, while delayed-onset events (&gt;20 days) were linked to five others. This study highlights diverse AE profiles of TCEs, providing insights for clinicians to optimize their safe use in practice.
DOI: 10.6084/m9.figshare.28458680.v1
title: Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database

description: T-cell engagers (TCEs) are transformative immunotherapies with significant potential in treating hematologic malignancies and solid tumors. However, their real-world safety profiles remain inadequately characterized. Using the FDA Adverse Event Reporting System (FAERS) database (October 2019 – September 2024, 8,747,158 reports), we analyzed adverse events (AEs) associated with nine TCEs. Disproportionality analysis identified overreported AEs, with 11,963 unique reports analyzed after deduplication. Blinatumomab was the most reported TCE (<i>n</i> = 4,950), and Tarlatamab the least (<i>n</i> = 185). Predominant AEs included immune system disorders, particularly cytokine release syndrome (IC<sub>025</sub> range: 6.08–7.47). Drug-specific signals included reproductive system and breast disorders (IC<sub>025</sub>: 2.74) and vascular disorders (IC<sub>025</sub>: 2.25) with Tebentafusp, renal and urinary disorders with Epcoritamab (IC<sub>025</sub>: 1.84), and eye disorders with Elranatamab (IC<sub>025</sub>: 1.81). Novel AEs were also uncovered, including second malignant neoplasms, vasogenic cerebral edema with Mosunetuzumab (IC<sub>025</sub>: 5.77, ROR<sub>025</sub>: 56.29), and hydronephrosis with Epcoritamab (IC<sub>025</sub>: 7.50, ROR<sub>025</sub>: 180.70). Early-onset events (0.5–9.5 days) were linked to four TCEs, while delayed-onset events (&gt;20 days) were linked to five others. This study highlights diverse AE profiles of TCEs, providing insights for clinicians to optimize their safe use in practice.
DOI: 10.6084/m9.figshare.28379172
title: Cardiovascular toxicities of hypoxia-inducible factor prolyl hydroxylase inhibitors: a disproportionality analysis based on JADER database

description: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have shown promising prospects as novel therapeutic agents in renal anemia, but their potential cardiovascular toxicities have raised widespread concern. This study aim to explore the cardiovascular toxicities associated with HIF-PHIs through real-world long-term safety data. A disproportionality analysis was employed by calculating the reporting odds ratios (ROR), information component (IC), and their 95% credibility intervals (CrI) in Japan Adverse Drug Event Report (JADER) database from 1 January 2020, to 30 September 2023. From Q1 2020 to Q3 2023, 253,599 adverse events (AEs) cases were extracted from the JADER database, including 4,015 cases related to HIF-PHIs and 1,537 (38.28%) cases of cardiovascular toxicities. Embolic and thrombotic events (ROR = 6.66, IC = 2.74), cardiac failure (ROR = 3.86, IC = 1.95), and ischemic heart disease (ROR = 3.37, IC = 1.75) indicated positive signals in HIF-PHIs. The median time to onset (TTO) of hypertension for HIF-PHIs was noted to be the earliest at 15.50 days. HIF-PHIs are related to multiple cardiovascular toxicities. Although disproportionality analysis is a hypothesis-driven method, improving the surveillance of these toxicities related to HIF-PHIs used in managing renal anemia is still crucial.
DOI: 10.6084/m9.figshare.28379172.v1
title: Cardiovascular toxicities of hypoxia-inducible factor prolyl hydroxylase inhibitors: a disproportionality analysis based on JADER database

description: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have shown promising prospects as novel therapeutic agents in renal anemia, but their potential cardiovascular toxicities have raised widespread concern. This study aim to explore the cardiovascular toxicities associated with HIF-PHIs through real-world long-term safety data. A disproportionality analysis was employed by calculating the reporting odds ratios (ROR), information component (IC), and their 95% credibility intervals (CrI) in Japan Adverse Drug Event Report (JADER) database from 1 January 2020, to 30 September 2023. From Q1 2020 to Q3 2023, 253,599 adverse events (AEs) cases were extracted from the JADER database, including 4,015 cases related to HIF-PHIs and 1,537 (38.28%) cases of cardiovascular toxicities. Embolic and thrombotic events (ROR = 6.66, IC = 2.74), cardiac failure (ROR = 3.86, IC = 1.95), and ischemic heart disease (ROR = 3.37, IC = 1.75) indicated positive signals in HIF-PHIs. The median time to onset (TTO) of hypertension for HIF-PHIs was noted to be the earliest at 15.50 days. HIF-PHIs are related to multiple cardiovascular toxicities. Although disproportionality analysis is a hypothesis-driven method, improving the surveillance of these toxicities related to HIF-PHIs used in managing renal anemia is still crucial.
DOI: 10.6084/m9.figshare.26575486
title: Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus

description: Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics. We collected literature on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. Thirty-seven patients (33 females and 4 males) were included. The patients have a median age of 49.5 years (range 18–79) and onset time of 5 weeks (range 1–12). SCLE is mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%), and maculopapular erythematous (13.9%). Mainly, histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%), and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%), and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7–84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine, and immunosuppressant. No recurrence was observed within 12 months (range 1.5–48) of follow-up. These results suggest that terbinafine-induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combined with hydroxychloroquine may be an effective treatment.
DOI: 10.6084/m9.figshare.26575486.v2
title: Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus

description: Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics. We collected literature on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. Thirty-seven patients (33 females and 4 males) were included. The patients have a median age of 49.5 years (range 18–79) and onset time of 5 weeks (range 1–12). SCLE is mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%), and maculopapular erythematous (13.9%). Mainly, histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%), and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%), and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7–84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine, and immunosuppressant. No recurrence was observed within 12 months (range 1.5–48) of follow-up. These results suggest that terbinafine-induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combined with hydroxychloroquine may be an effective treatment.
DOI: 10.6084/m9.figshare.26575486.v1
title: Analysis of clinical characteristics of terbinafine-induced subacute cutaneous lupus erythematosus

description: Terbinafine may cause subacute cutaneous lupus erythematosus (SCLE), and we aimed to analyze its clinical characteristics. We collected literatures on terbinafine-induced SCLE from 1997 to 2023 for retrospective analysis. 37 patients (33 females and 4 males) were included. The patients have a median age of 49.5 years (range 18-79) and onset time of 5 weeks (range 1-12). SCLE mainly manifested as annular erythematous (83.3%), scaly erythematous (44.4%) and maculopapular erythematous (13.9%). Mainly histopathological manifestations are lymphocytic infiltrate (55.6%), hyperkeratosis (38.9%) and keratinocyte necrosis (38.9%). Positive immunological parameters mainly include antinuclear antibody (100.0%), anti-Ro/SSA antibody (94.1%) and anti-La/SSB antibody (72.2%). Past medical history usually includes photosensitivity (33.3%), inflammatory disease (33.33%) and lupus erythematosus (12.1%). Symptoms are completely resolved within a median time of 35 days (range 7-84) after discontinuation of terbinafine and treatment with topical corticosteroids, systemic corticosteroids, hydroxychloroquine and immunosuppressant. No recurrence was observed within 12 months (range 1.5-48) of follow-up. These results suggest that terbinafine induced SCLE should be comprehensively diagnosed based on clinical symptoms, histopathological manifestations, immunological parameters, and past medical history. Terbinafine should be immediately discontinued when SCLE occurs, while systemic and topical corticosteroids combine with hydroxychloroquine may be an effective treatment.
DOI: 10.6084/m9.figshare.28238141.v1
title: Risk assessment of venetoclax-associated adverse events: a meta-analysis approach

description: Venetoclax, an oral B-cell lymphoma-2 (BCL-2) inhibitor, shows promise in cancer treatment but has an unclear safety profile. This meta-analysis evaluates the safety of venetoclax, focusing on adverse events. Data from PubMed, Embase, Cochrane databases, and ClinicalTrials.gov were retrieved up to August 2023. Nine studies were included based on specific inclusion and exclusion criteria. A random effects model was used to calculate risk ratios (RRs) and 95% confidence intervals (CIs). The meta-analysis included nine studies. Venetoclax was associated with increased risks of neutropenia (RR = 1.427, 95% CI = 1.118 to 1.822), diarrhea (RR = 1.889, 95% CI = 1.388 to 2.570), and cardiovascular events (RR = 1.726, 95% CI = 1.088 to 2.737). However, the risk of tumor lysis syndrome (TLS) with venetoclax was not increased compared to the comparators (RR = 1.478, 95% CI = 0.504 to 4.337). Venetoclax increases the risk of hematological, gastrointestinal, and cardiac adverse events. Clinicians should monitor these side effects, especially in patients with preexisting conditions. Further research is needed to fully understand venetoclax’s safety profile. https://inplasy.com/ identifier is INPLASY2023110041